Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers

Abreu, 2001, Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans, Psychopharmacology (Berl.), 154, 76, 10.1007/s002130000624 Alho, 2007, Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users, Drug Alcohol Depend., 88, 75, 10.1016/j.drugalcdep.2006.09.012 Babalonis, 2013, Abuse liability and reinforcing efficacy of oral tramadol in humans, Drug Alcohol Depend., 129, 116, 10.1016/j.drugalcdep.2012.09.018 Barrau, 2001, Comparison of methadone and high dosage buprenorphine users in French care centres, Addiction, 96, 1433, 10.1046/j.1360-0443.2001.961014337.x Berkowitz, 1976, The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone, Clin. Pharmacokinet., 1, 219, 10.2165/00003088-197601030-00004 Bruce, 2009, Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market, Am. J. Drug Alcohol Abuse, 35, 68, 10.1080/00952990802585406 Cicero, 2013, Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States, Pain, 154, 2639, 10.1016/j.pain.2013.07.025 Clark, 2002, Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose, Med. J. Aust., 176, 166 Cowan, 1977, Agonist and antagonist properties of buprenorphine: a new antinociceptive agent, Br. J. Pharmacol., 60, 537, 10.1111/j.1476-5381.1977.tb07532.x CSAT, 2004 de Wit, 1992, Rate of increase of plasma drug level influences subjective response in humans, Psychopharmacology (Berl.), 107, 352, 10.1007/BF02245161 de Wit, 1993, Subjective and behavioral effects of diazepam depend on its rate of onset, Psychopharmacology (Berl.), 112, 324, 10.1007/BF02244928 Eiden, 2013, Acute hepatitis and renal failure related to intranasal buprenorphine misuse: case report and analysis of cases reported to the French network for drug monitoring, Ann. Pharmacother, 47, 1721, 10.1177/1060028013507429 Eissenberg, 1996, Buprenorphine’s physical dependence potential: antagonist-precipitated withdrawal in humans, J. Pharmacol. Exp. Ther., 276, 449 Ferrant, 2011, Fatal poisoning due to snorting buprenorphine and alcohol consumption, Forensic Sci. Int., 204, e8, 10.1016/j.forsciint.2010.05.015 Fudala, 1998, Effects of buprenorphine and naloxone in morphine-stablized opioids addicts, Drug Alcohol Depend., 50, 1, 10.1016/S0376-8716(98)00008-8 Fullerton, 2014, Medication-assisted treatment with methadone: assessing the evidence, Psychiatr. Serv., 65, 146, 10.1176/appi.ps.201300235 Handelsman, 1987, Two new rating scales for opiate withdrawal, Am. J. Drug Alcohol Abuse, 13, 293, 10.3109/00952998709001515 Harris, 2000, Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine, Drug Alcohol Depend., 61, 85, 10.1016/S0376-8716(00)00126-5 Hayes, 2008, Toxicity of buprenorphine overdoses in children, Pediatrics, 121, e782, 10.1542/peds.2007-1774 Himmelsbach, 1941, The morphine abstinence syndrome: its nature and treatment, Ann. Intern. Med., 15, 829, 10.7326/0003-4819-15-5-829 Horyniak, 2011, The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia, Int. J. Drug Policy, 22, 167, 10.1016/j.drugpo.2010.10.004 Jasinski, 1977, Progress report from the clinical pharmacology section of the NIDA addiction research center, 39th Annual Meeting The Committee on Problems of Drug Dependence, 133 Jenkinson, 2005, Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?, Addiction, 100, 197, 10.1111/j.1360-0443.2004.00958.x Johnson, 2000, Buprenorphine and naloxone for heroin dependence, Curr. Psychiatry Rep., 2, 519, 10.1007/s11920-000-0012-8 Jones, 2015, Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users, Addict. Biol., 20, 784, 10.1111/adb.12163 Kintz, 2002, A new series of 13 buprenorphine-related deaths, Clin. Biochem., 35, 513, 10.1016/S0009-9120(02)00304-1 Lai, 2006, Buprenorphine-associated deaths in Singapore, Ann. Acad. Med. Singap., 35, 508 Larance, 2014, The diversion and injection of a buprenorphine-naloxone soluble film formulation, Drug Alcohol Depend., 136, 21, 10.1016/j.drugalcdep.2013.12.005 Lavonas, 2013, Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children, J. Pediatr., 163, 1377, 10.1016/j.jpeds.2013.06.058 Lofwall, 2014, A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world, J. Addict. Med., 8, 315, 10.1097/ADM.0000000000000045 Lovegrove, 2014, Emergency hospitalizations for unsupervised prescription medication ingestions by young children, Pediatrics, 134, e1009, 10.1542/peds.2014-0840 Mattick, 2014, Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence, Cochrane Database Syst. Rev., 2, CD002207 McLellan, 1992, The fifth edition of the addiction severity index, J. Subst. Abuse Treat., 9, 199, 10.1016/0740-5472(92)90062-S Megarbane, 2011, Fatalities in relation to buprenorphine snorting and ethanol co-ingestion: mechanisms of toxicity, Forensic Sci. Int., 207, e59, 10.1016/j.forsciint.2010.09.014 Mendelson, 1996, Buprenorphine and naloxone interactions in opiate-dependent volunteers, Clin. Pharmacol. Ther., 60, 105, 10.1016/S0009-9236(96)90173-3 Middleton, 2011, The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers, Addiction, 106, 1460, 10.1111/j.1360-0443.2011.03424.x Nordmann, 2012, Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey, Pharmacoepidemiol. Drug Saf., 21, 184, 10.1002/pds.2263 Preston, 1998, Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose, Behav. Pharmacol., 9, 533, 10.1097/00008877-199811000-00009 Preston, 1988, Buprenorphine and naloxone alone and in combination in opioid-dependent humans, Psychopharmacology (Berl.), 94, 484, 10.1007/BF00212842 Preston, 1990, Effects of sublingually given naloxone in opioid-dependent volunteers, Drug Alcohol Depend., 25, 27, 10.1016/0376-8716(90)90136-3 Reynaud, 1998, Six deaths linked to concomitant use of buprenorphine and benzodiazepines, Addiction, 93, 1385, 10.1046/j.1360-0443.1998.93913859.x Rosado, 2007, Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone, Drug Alcohol Depend., 90, 261, 10.1016/j.drugalcdep.2007.04.006 Roux, 2008, Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France, Addict. Behav., 33, 1625, 10.1016/j.addbeh.2008.07.018 Schuh, 1996, Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans, J. Pharmacol. Exp. Ther., 278, 836 Simonsen, 2011, Fatal poisoning in drug addicts in the Nordic countries in 2007, Forensic Sci. Int., 207, 170, 10.1016/j.forsciint.2010.10.001 Stoller, 2001, Effects of buprenorphine/naloxone in opioid-dependent humans, Psychopharmacology (Berl.), 154, 230, 10.1007/s002130000637 Tracqui, 1998, Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities, J. Anal. Toxicol., 22, 430, 10.1093/jat/22.6.430 Walsh, 1994, Clinical pharmacology of buprenorphine: ceiling effects at high doses, Clin. Pharmacol. Ther., 55, 569, 10.1038/clpt.1994.71 Walsh, 1995, Effects of buprenorphine and methadone in methadone-maintained subjects, Psychopharmacology (Berl.), 119, 268, 10.1007/BF02246290 Watson, 1998, Opioid toxicity recurrence after an initial response to naloxone, J. Toxicol. Clin. Toxicol., 36, 11, 10.3109/15563659809162577 Wesson, 2003, The clinical opiate withdrawal scale (COWS), J. Psychoact. Drugs, 35, 253, 10.1080/02791072.2003.10400007 Young, 2010, Route of administration for illicit prescription opioids: a comparison of rural and urban drug users, Harm Reduct. J., 7, 24, 10.1186/1477-7517-7-24